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quired cataract surgery. At 5 years’ follow-up, the patient is 
tumor free with normal vision (20/20 in both eyes), full bin-
ocularity, and no metastasis.  Conclusions: The present bi-
cameral injection technique appears to be safe and effective 
with limited toxicity. Melphalan-induced side effects were 
noted on the iris and lens but with no impact on the final vi-
sual function.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Seeding in retinoblastoma has always been recognized 
as a poor prognostic factor, but it has only recently been 
classified into 3 classes of seeds  [1] . The advent of novel 
routes of antimitotic drug administration, such as oph-
thalmic artery  [2] and vitreous injections  [3] , completely 
reversed the negative prognostic value of subretinal and 
vitreous seeds, respectively. However, all attempts to con-
trol aqueous seeding remained unsuccessful until very re-
cently  [4] , when brachytherapy was successfully used for 
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 Abstract 
 Background: The anterior chamber has been shown by 
pharmacokinetic studies to represent a sanctuary never 
achieving a tumoricidal dose with the present administra-
tion routes, such as systemic, intra-arterial, or intravitreal in-
jections.  Method: A novel intracameral chemotherapy tech-
nique is described to control aqueous seeding in a pilot uni-
lateral group E retinoblastoma case with primary aqueous 
seeding. Anterior segment toxicity was carefully monitored. 
 Results: Control of the retinal tumor and vitreous seeding 
was achieved by intra-arterial and intravitreal chemothera-
pies. Sterilization of the aqueous was achieved after a first 
cycle of 7 melphalan injections in the anterior chamber, but 
relapse was noted 3.5 months later. This relapse was finally 
controlled with a second cycle of 6 intracameral injections 
targeting the posterior chamber. Corneal endothelial cell 
density remained stable over the injection period. Hetero-
chromia and a progressive cataract developed, which re-
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diffuse anterior retinoblastoma not involving the retina. 
Aqueous seeding is still considered to be one of the abso-
lute criteria for enucleation (group E in the International 
Intraocular Retinoblastoma Classification) and is present 
in 1% of cases at presentation on biomicroscopy  [5] and 
in 30% of cases on histopathology in primarily enucleated 
group E eyes  [6] . This frequency rises to 65%  [7] and even 
100%  [8] in cases of diffuse infiltrative and anterior dif-
fuse variants of retinoblastoma, respectively. The occur-
rence of secondary aqueous seeding in the course of con-
servative treatment also results in a 100% enucleation 
rate. Here, we present a novel technique of in situ chemo-




 Fig. 1.  a Biomicroscopy and gonioscopy at 
presentation: pseudohypopyon (white tri-
angle); iris nodules at 6 and 9 o’clock and 
nodules in the angle over 270° (white ar-
rows).  b Ultrasonic biomicroscopy (35 
mHz) at presentation: circular invasion of 
the posterior chamber, including the canals 
of Petit and Hannover, but no involvement 
of the ciliary body, iris, or Schlemm’s canal. 
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 Case Presentation 
 This study was approved by the Swiss Federal Department of 
Health (authorization No. 035.0003-48) and is in accordance 
with the declaration of Helsinki. An 11-year-old girl presented 
with unilateral group E anterior diffuse retinoblastoma in the 
left eye and normal vision in both eyes with full binocularity. 
Biomicroscopic examination showed cells floating in the ante-
rior chamber (AC) as well as a pseudohypopyon and 2 iris nod-
ules at 6 and 9 o’clock ( Fig. 1 a). Gonioscopy revealed numerous 
nodules growing in the angle over 270° ( Fig. 1 a). Ultrasonic bio-
microscopy (UBM) at 35 mHz documented a circular invasion 
of the posterior chamber, including the canals of Petit and Han-
nover, but no involvement of the ciliary body, iris, or Schlemm’s 
canal ( Fig.  1 b). Anterior segment fluorescein angiography 
showed infraclinical (not visible on biomicroscopy) rubeosis iri-
dis of the collarette (data not shown). The intraocular pressure 
was 30 mm Hg in the left eye (18 mm Hg in the right eye) under 
tri-therapy. Fundus examination displayed massive inferiorly 
located vitreous seeding type III (cloud) masking the primary 
peripheral tumor ( Fig. 2 a), which measured 2.3 × 2.3 × 1.2 mm 
at 5: 30 by UBM under the vitreous base ( Fig. 2 b). There was no 
retinal detachment, and both macula and optic nerve head were 
tumor free. 
 A conservative therapeutic strategy was designed to control ret-
inal, vitreous, and cameral disease consisting of melphalan injec-
tions as follows: intra-arterial (2× with a total dose of 10 mg) fol-
lowed by concomitant intravitreal (6× with a total dose of 216 μg) 
and intracameral (7× with a total dose of 15.8 μg). Intra-arterial and 
intravitreal chemotherapies were performed as previously described 
 [9, 10] . The technique of intracameral injection, performed under 
pharmacologic suppression of aqueous secretion (acetazolamide
5 mg/kg), is described in  Figure 3 and illustrated by a video







 Fig. 2.  a Fundus montage at presentation: 
inferiorly located vitreous seeding type III 
(cloud) masking the primary peripheral tu-
mor.  b ,  c Ultrasonic biomicroscopy (35 
mHz) of the primary peripheral tumor un-
der the vitreous base ( b ) and tumor inva-
sion of the posterior chamber ( c ) at presen-
tation.  d Fundus montage at full remission. 
 e Ultrasonic biomicroscopy at complete re-
mission: tumor-free posterior chamber.
 f ,  g Gonioscopy at first remission ( f ) and at 
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karger.com/doi/10.1159/000453617). The concentration of mel-
phalan injected in the AC was 6 μg/mL (3×) at the beginning and 
was progressively increased to 8 μg/mL (2×) and 10 μg/mL (2×) with 
no effect on endothelial cell density as monitored by confocal mi-
croscopy. 
 Anterior segment involvement being a controversial risk factor 
for metastasis, the issue of preventive systemic chemotherapy was 
delayed. However, at the end of this first-line eye-targeted treat-
ment, 4 monthly cycles of systemic preventive chemotherapy (eto-
poside and carboplatin) were given.
 All 3 compartments were under control with time to success for 
retina, vitreous, and anterior segment of 24, 107, and 89 days, re-
spectively ( Fig. 2 d–f). The tumor response in the AC was moni-
tored by cytopathological analysis ( Fig.  4 a–c) and cell culture 
( Fig. 4 d–g). Cytopathology was initially positive for retinoblasto-
ma cells and spheres staining positive for synaptophysin ( Fig. 4 c) 
but was found to be negative following the second intracameral 
injection. As documented by cell culture, both the number of ag-
gregates ( Fig. 4 d) and cells per aggregate ( Fig. 4 e) dropped to zero 
following the second intracameral injection, with the number of 
individual living cells nullified reaching 100% Trypan blue-posi-
tive cells after the third injection ( Fig. 4 f, g).
 An aqueous relapse was noted 3.5 months later on gonioscopy 
( Fig. 2 g) and cell culture ( Fig. 4 d–g), arising from the posterior 
chamber. Considering that the initial 7 intracameral injections 
were delivered to the AC only, we hypothesized that the recurrence 
was caused by an underdosage of melphalan in the posterior cham-
ber secondary to drug dilution by ciliary secretion and inverse iri-
dolenticular block occurring during the injection when performed 
in the AC alone. The injection technique was modified to target 
the posterior chamber across the peripheral iris with 6 combined 
AC and posterior chamber injections (15 μg/mL with a total dose 
of 35 μg). Four concomitant intravitreal injections (total dose of 
140 μg) were applied to prevent any cross-contamination between 
the vitreous and aqueous compartments. Complete and stable re-








 Fig. 3. Technique of intracameral injection. 
 a ,  a’ Long-needle passage (34 G) across pe-
ripheral clear cornea.  b Complete aspira-
tion of the aqueous volume contained in 
the anterior and posterior chambers. This 
maneuver is facilitated by indenting the eye 
with a scleral depressor (not illustrated) 
just posteriorly to the limbus (see online 
suppl. video).  c Syringe exchange with mel-
phalan at a concentration of 15 μg/mL.
 d Melphalan injection of 1/3 (paracentesis 
volume minus the volume to be injected 
into the vitreous) into the anterior cham-
ber.  e Perforation of the iris root at a tu-
mor-free meridian selected by ultrasonic 
biomicroscopy to position the needle in the 
posterior chamber.  f Transiridal injection 
into the posterior chamber of the remain-
ing 2/3 (paracentesis volume minus the 
volume to be injected into the vitreous) 
with anterior chamber retrofilling. In total, 
the mean intracameral injection volume 
was 0.35 mL.  g Triple freeze and thaw cryo-
application at the entry site. 
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 Fig. 4. Monitoring of tumor response in the anterior chamber by 
cytopathological analysis ( a–c ) and cell culture ( d–g ).  a Isolated, 
small- to medium-sized malignant cells with granular chromatin 
and scant cytoplasm. Some apoptotic nuclei are present in the 
background (liquid-based cytology, Papanicolaou staining, ×400). 
 b Bright-field micrograph (×400) of 1 out of 5 aggregates detected 
in culture after the first sampling (January 9, 2012).  c A group of 
malignant cells express the immunocytochemical marker syn-
aptophysin (clone 27G12, dilution 1: 100, Leica Biosystems), con-
sistent with retinoblastoma cells (liquid-based cytology, ×400).
 d–g Quantification of the number of aggregates ( d ), cells per ag-
gregate ( e ), individual cells ( f ), and dying cells (Trypan blue posi-
tive) ( g ) calculated on samples harvested before each intracameral 
injection. 20120109, 20120119, 20120130, 20120209, 20120628, 
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 In terms of toxicity, the patient developed hypochromic het-
erochromia, with no pigment epithelial loss (no iris transillumina-
tion) and no stromal thinning on UBM ( Fig. 5 a, b), and cortical 
opacification of the lens ( Fig. 5 c–f) 7 months after the first intra-
cameral injection, requiring cataract surgery with intraocular mul-
tifocal lens implantation 15 months later. Corneal endothelial cell 
density was monitored from presentation and remained un-
changed over the injection period with a slight drop of <2% after 
the cataract surgery (pre- and postoperative mean cell count was 
2,724 and 2,673 cells/mm 2 , respectively, with no morphologic 
changes). 
 At 5 years’ follow-up, the patient is tumor free with binocular 
normal vision (20/20 in both eyes). Molecular genetic blood anal-
ysis by sequencing did not reveal any RB1 mutation.
 Discussion 
 Aqueous seeding has remained an intractable form of 
retinoblastoma due to a sanctuary effect linked to insuf-
ficient drug bioavailability in the AC, despite direct oph-
thalmic artery or intravitreal delivery, to achieve an anti-
tumor effect  [11] .
 Anterior segment invasion as a risk factor for metasta-
sis, although controversial, is not considered to add a sig-
nificant risk for extraocular relapse when isolated  [12, 
13] . Its presence is, however, synonymous with enucle-
ation. Earlier this year, Shields et al.  [4] published the first 
successful attempt to control aqueous seeding in 3 eyes 
with anterior diffuse retinoblastoma devoid of any retinal 
or vitreous involvement by means of iodine plaque ther-
apy delivered to the entire anterior segment, including 
the ciliary body. At a mean follow-up of 35 months, these 
authors report complete remission in all 3 cases and sat-
isfactory visual outcome despite the occurrence of a ra-
dio-induced cataract requiring surgery at a mean follow-
up of 16 months. Corneal limbal stem cell insufficiency 
and radiation-induced glaucoma are, however, likely to 
compromise long-term functional results. Given that the 
tumor thickness ranged from 3 to 9 mm, the peripheral 
retina, macula, and optic nerve head were also exposed to 
a potentially sight-threatening dose of radiation. In addi-
tion, the lateral dosimetry characterizing high-energy 
gamma Curie therapy cannot entirely spare the normal 
surrounding orbit, which would be contraindicated in a 
germline RB1 carrier.
 In the present report, we describe a safe and efficient 
way to control aqueous seeding provided that (1) the in-
a b
c d e f
 Fig. 5. Iris and lens toxicity.  a ,  b Biomicroscopic views of the iris with hypochromic heterochromia.  c ,  d Biomi-
croscopic views of cortical opacification of the lens.  e ,  f Scheimpflug photography of cortical opacification of the 
lens. 
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jection is targeting both anterior and posterior chambers 
across the iris root at a tumor-free meridian selected by 
UBM, (2) the concentration of the injected solution of 
melphalan is higher than the tumoricidal dose found in 
vitro by Inomata and Kaneko  [14] , (3) the ciliary secre-
tion is pharmacologically suppressed to prevent dilution 
of the drug, (4) the source of the seeding is destroyed to 
prevent relapse, and (5) the vitreous is concomitantly in-
jected to prevent vitreous-to-aqueous cross-contamina-
tion. The toxicity encountered was limited to the lens and 
iris, preserving long-term visual potential. 
 To the best of our knowledge, this is the first report of 
a cure for seeding in the aqueous arising from a vitreo-
retinal tumor source. More recently, we had a second pa-
tient who developed secondary aqueous seeding linked to 
a peripheral ciliary relapse. The same protocol was ap-
plied to control the aqueous seeding concomitantly with 
a plaque centered on the ciliary body, but without sys-
temic preventive chemotherapy  [13] . Complete remis-
sion was obtained with an event-free follow-up of 3 years 
 [15] . Since then, intracameral chemotherapy has benefit-
ed 10 additional cases [Munier F.L. et al., in preparation]. 
In addition, this protocol was made available across Eu-
rope on request and was successfully administered in at 
least 1 patient with only 1 eye [Desjardin L., pers. com-
mun.].
 In summary, we have described a new route of target-
ed chemotherapy consisting of direct intracameral deliv-
ery of melphalan. The associated toxicity is compatible 
with long-term preservation of the visual function, in-
cluding normal visual acuity and full binocularity, as 
shown here. 
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